enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. List of antineoplastic agents - Wikipedia

   en.wikipedia.org/wiki/List_of_antineoplastic_agents

   Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.

3. Proxalutamide - Wikipedia

   en.wikipedia.org/wiki/Proxalutamide

   Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.

4. Nonsteroidal antiandrogen - Wikipedia

   en.wikipedia.org/wiki/Nonsteroidal_antiandrogen

   Bicalutamide (Casodex): Marketed for the treatment of prostate cancer and also used in the treatment of hirsutism in women, [4] as a component of hormone therapy for transgender women, [5] to delay precocious puberty in boys, [7] to prevent or alleviate priapism, [8] and for other indications.

5. JNJ-26146900 - Wikipedia

   en.wikipedia.org/wiki/JNJ-26146900

   The drug is a nonsteroidal androgen receptor (AR) modulator with mixed agonistic and antagonistic (antiandrogenic) effects. [2] [6] In animals, it partially prevents castration-induced loss of body weight, lean body mass (LBM), and bone and reduces prostate weight and prostate tumor growth.

6. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

7. Leuprorelin - Wikipedia

   en.wikipedia.org/wiki/Leuprorelin

   On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camcevi, intended for the treatment of the cancer of the prostate in adult men when the cancer is "hormone-dependent ...